My name is Ian Jang, and I am the BD Team Manager responsible for in-licensing and market alliance activities for the Korean market. Through the CPHI conference, I am seeking potential licensing opportunities, primarily focused on biosimilars, value-added medicines, and non-infringing formulations suited for the Korean market. Please note that I am not responsible for out-licensing, API business, regulatory affairs, or R&D collaborations. Therefore, I kindly ask for your understanding that I will decline meeting requests from API manufacturers or service providers during the conference. I look forward to exploring possible partnerships and mutually beneficial opportunities.